Human dendritic cells engineered to express alpha tumor necrosis factor maintain cellular maturation and T-cell stimulation capacity

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 6, 2006, Pages 613-622

  Ye, Zhenmin ^a   Chen, Zhuang ^a   Sami, Amer ^a   El Gayed, Ali ^a   Xiang, Jim ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b Saskatoon Cancer Center   (Canada)

Author keywords

Adenovirus; Dendritic cell; Maturation; T cell stimulation; TNF

Indexed keywords

B7 ANTIGEN; CD14 ANTIGEN; CD19 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CYTOKINE; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; T6 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS; ARTICLE; CANCER IMMUNIZATION; CELL MATURATION; CONTROLLED STUDY; CULTURE MEDIUM; DENDRITIC CELL; EX VIVO STUDY; FETAL CALF SERUM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ENGINEERING; T LYMPHOCYTE ACTIVATION; TRANSGENE; TUMOR IMMUNITY; VIRUS RECOMBINANT;

ADENOVIRIDAE; CELL DIFFERENTIATION; CELLS, CULTURED; CULTURE MEDIA, SERUM-FREE; DENDRITIC CELLS; GENE EXPRESSION; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; PHENOTYPE; PROTEIN ENGINEERING; RECEPTORS, CHEMOKINE; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846648644     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.613     Document Type: Article

References (42)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392(6673):245.
2. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation, and antigen-presenting function of dendritic cells. Curr Opin Immunol 1997;9(1):10.
3. Nair SK, Snyder D, Rouse BT, et al. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997;70(6):706.
4. Jonuleit H, Knop J, Enk AH. Cytokines and their effects on maturation, differentiation, and migration of dendritic cells. Arch Dermatol Res 1996;289(1):1.
5. Caux C, Dezutter-Dambuyant C, Schmitt D, et al. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992;360 (6401):258.
6. Jonuleit H, Kuhn U, Muller G, et al. Proinflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997;27(12):3135.
7. Labeur MS, Roters B, Pers B, et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 1999;162(1):168.
8. Spisek R, Bougras G, Ebstein F, et al. Transient exposure of dendritic cells to maturation stimuli is sufficient to induce complete phenotypic maturation while preserving their capacity to respond to subsequent restimulation. Cancer Immunol Immunother 2003;52(7):445.
9. Chen Z, Dehm S, Bonham K, et al. DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficacy. Cell Immunol 2001;214(1):60.
10. Thurner B, Roder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Meth 1999;223(1):1.
11. Berger TG, Feuerstein B, Strasser E, et al. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Meth 2002;268(2):131.
12. Matsuura K, Yamaguchi Y, Ueno H, et al. Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer 2006;106(6):1227.
13. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004;10(9):909.
14. Royer PJ, Tanguy-Royer S, Ebstein F, et al. Culture medium and protein supplementation in the generation and maturation of dendritic cells. Scand J Immunol 2006;63(6):401.
15. Voigtlander C, Rossner S, Cierpka E, et al. Dendritic cells matured with TNF can be further activated in vitro and after subcutaneous injection in vivo which converts their tolerogenicity into immunogenicity. J Immunother 2006;29(4):407.
16. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood: An improved method with special regard to clinical applicability. J Immunol Meth 1996;196(2):137.
17. Rieser C, Bock G, Klocker H, et al. Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: Synergistic activation of interleukin-12 production. J Exp Med 1997;186(9):1603.
18. Brunner C, Seiderer J, Schlamp A, et al. Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T-cell activation in vitro and therapeutic antitumor immune responses in vivo. J Immunol 2000;165(11):6278.
19. Cumberbatch M, Kimber I. Tumour necrosis factor-alpha is required for accumulation of dendritic cells in draining lymph nodes and for optimal contact sensitization. Immunology 1995;84(1):31.
20. Brossait P, Zobywalski A, Grunebach F, et al. Tumor necrosis factor-alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res 2000; 60(16):4485.
21. Zhang W, Chen Z, Li F, et al. Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and antitumour immunity than DCs generated in recombinant TNF-alpha. Immunology 2003;108(2):177.
22. Wright P, Braun R, Babiuk L, et al. Adenovirus-mediated TNF-alpha gene transfer induces significant tumor regression in mice. Cancer Biother Radiopharm 1999; 14(1):49.
23. Anton D, Dabadghao S, Palucka K, et al. Generation of dendritic cells from peripheral blood adherent cells in medium with human serum. Scand J Immunol 1998; 47(2):116.
24. Peng JC, Thomas R, Nielsen LK. Generation and maturation of dendritic cells for clinical application under serum-free conditions. J Immunother 2005;28(6):599.
25. Haase C, Ejrnaes M, Juedes AE, et al. Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivo. Blood 2005;106(13):4225.
26. Mackensen A, Drager R, Schlesier M, et al. Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother 2000;49(3):152.
27. Toldbod HE, Agger R, Bolund L, et al. Potent influence of bovine serum proteins in experimental dendritic cell-based vaccination protocols. Scand J Immunol 2003; 58(1):43.
28. + dendritic cells. Proc Natl Acad Sci USA 1996;93(6):2588.
29. Dietz AB, Vuk-Pavlovic S. High-efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 1998;91(2):392.
30. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2(10):1096.
31. Miller PW, Sharma S, Stolina M, et al. Dendritic cells augment granulocyte-macrophage colony-stimulating factor (GM-CSF)/herpes simplex virus thymidine kinase-mediated gene therapy of lung cancer. Cancer Gene Ther 1998;5(6):380.
32. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4(3):328.
33. Miller PW, Sharma S, Stolina M, et al. Intratumoral administration of adenoviral interleukin-7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther 2000; 11(1):53.
34. Tuting T, Wilson CC, Martin DM, et al. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T-cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J Immunol 1998; 160(3):1139.
35. Nishioka Y, Hirao M, Robbins PD, et al. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin-12. Cancer Res 1999;59 (16):4035.
36. Curiel-Lewandrowski C, Mahnke K, Labeur M, et al. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity. J Immunol 1999;163(1):174.
37. Tsung K, Meko JB, Peplinski GR, et al. IL-12 induces T-helper 1-directed antitumor response. J Immunol 1997;158(7):3359.
38. Kohno K, Kataoka J, Ohtsuki T, et al. IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol 1997; 158(4):1541.
39. Sozzani S, Locati M, Allavena P, et al. Chemokines: A superfamily of chemotactic cytokines. Int J Clin Lab Res 1996;26(2):69.
40. Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998;188(2):373.
41. Kellermann SA, Hudak S, Oldham ER, et al. The CC chemokine receptor-7 ligands oCkine and macrophage inflammatory protein-3 beta are potent chemoattractants for in vitro- and in vivo-derived dendritic cells. J Immunol 1999;162(7):3859.
42. Hirao M, Onai N, Hiroishi K, et al. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: Critical role in migration from the tumor site to draining lymph nodes. Cancer Res 2000;60(8):2209.